small molecule

VOQUEZNA

VONOPRAZAN FUMARATE

Loss of exclusivityMay 2032FDA regulatory exclusivity expiry

CompanyPhathom Pharmaceuticals →View the full company profile on CliffBio

Drug detail

Brand name	VOQUEZNA
Active ingredient	VONOPRAZAN FUMARATE
Strength	EQ 10MG BASE
Dosage form	TABLET
Route	ORAL
Modality	Small molecule
FDA approval	November 2023
Marketing status	RX

Listed patents

Patent	Expires	Type
9186411	August 2030	product
7977488	April 2030	substance

Regulatory exclusivity

Code	Expires
GAIN	May 2032
I-948	July 2027
NCE	May 2027
NP	November 2026

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the FDA regulatory exclusivity expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from Phathom Pharmaceuticals